{"id":5789,"date":"2006-02-11T18:07:23","date_gmt":"2006-02-11T17:07:23","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5789"},"modified":"2013-12-07T08:20:57","modified_gmt":"2013-12-07T08:20:57","slug":"clinical-experience-of-switching-to-atazanavir-in-the-uks-largest-clinic","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5789","title":{"rendered":"Clinical experience of switching to atazanavir in the UK\u0092s largest clinic"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Although atazanavir received approval in the US for treatment of both naive and experienced patients, approval in Europe was for treatment-experienced patients only. Nevertheless many clinics are using ritonavir-boosted atazanavir as first-line treatment, and as preferntial choice for switching patinets intollerant to efavirenz. Atazanavir requires once-daily dosing, has a low pill count and has good reported tolerability.<\/strong><\/p>\n<p>Holmes and colleagues from the Chelsea and Westminster Hospital, the UK\u0092s largest clinic, presented results from a prospective review of 241 patients who switched to atazanavir during the last 12 months (all but ten using ritonavir boosting). 89\/241 patients were PI-naive, 47 were single-PI experieced and 105 were multiple PI-experienced. Reasons for switching included adverse drug reaction (78), end of trial (28) and adherence (9).<\/p>\n<p>At week 48, by intent-to-treat analysis 60% and 57% of PI-naive and PI-experienced patients respectively achieved viral suppression &lt;50 copies\/mL, (72% and 64% were &lt;500 copies\/mL). Patients changing due to virological failure had a mean viral load decrease of \u00962.1 and \u00961.9 logs in the naive and experienced groups respectively. Rate of hypecholesterolaemia (&gt;6.5mmol\/L) dropped from 15% to 9% of patients. Mean bilirubin increase was 24 mmol\/L with four patients discontinuing atazanavir due to jaundice.<\/p>\n<p>Reference:<\/p>\n<p>Holmes PM, Tung M, Bower M et al. Atazanavir: 12 months of clinical experience in 241 individuals. 10th EACS, Dublin 2005. Abstract PE7.9\/9.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Although atazanavir received approval in the US for treatment of both naive and experienced patients, approval in Europe was for treatment-experienced patients only. Nevertheless many clinics are using ritonavir-boosted atazanavir as first-line treatment, and as preferntial &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[70],"class_list":["post-5789","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-eacs-10th-2005"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5789"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5789\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}